Loading
Latest filing published 13 Jan 2026 for LISATA THERAPEUTICS, INC., €5,039. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Kristen K. Buck (senior executive) discloses dealings in Lisata Therapeutics, Inc. to SEC (Form 4). In total, 13 filings cover trades dated from 1 September 2021 to 9 January 2026.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The record was last updated on 13 January 2026 with a share grant (€5,039) in Lisata Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations